LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a presentation at the 24th Annual Needham Virtual Healthcare Conference 2025 on Wednesday, April 9, at 8:00 a.m. ET.

The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at .

About Lexicon Pharmaceuticals 

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, obesity, cardiology, diabetes and other indications. For additional information, please visit . 

For Investor and Media Inquiries: 

Lisa DeFrancesco  

Lexicon Pharmaceuticals, Inc. 

 



EN
02/04/2025

Underlying

LXRXLexicon Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lexicon Pharmaceuticals Inc.

 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin...

Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025 THE WOODLANDS, Texas, Sept. 04, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: LXRX) today announced that the Company will present new data demonstrating the reduction of neuropathic pain by pilavapadin in preclinical models of chemotherapy-induced peripheral neuropathy (CIPN) and multiple sclerosis (MS) at the 9th International Congress on Neuropathic Pain - (NeuPSIG) 2025. The findings highlight the relevance of inhibiting pilavapadin’s novel target, AAK1, ...

September 4, 2025 1 EN
 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral ...

Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025 THE WOODLANDS, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: LXRX) today announced data from a study of patients describing the physical and psychological impact of diabetic peripheral neuropathic pain (DPNP), despite treatment with available over-the-counter and prescription pain relievers will be presented at PAINWeek 2025. The conference is being held September 2-4, 2025, at The Cosmopolitan in Las Vegas, Nevada. Presentation details: Poster #53: ...

September 3, 2025 1 EN
 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Fai...

Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress Oral presentation highlighted improvements in heart failure endpoints and major adverse cardiovascular events (MACE) among older adults irrespective of age THE WOODLANDS, Texas, Sept. 02, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: LXRX) announced that a post-hoc analysis (“Efficacy of Sotagliflozin Among Older Adults: A Pooled Analysis of SCORED and SOLOIST-WHF”) of...

September 2, 2025 1 EN
 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Confer...

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences THE WOODLANDS, Texas, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at Citi's Biopharma Back to School Conference on Wednesday, September 3 at 1:45 p.m. ET and at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8 at 3:00 p.m. ET. The live events and replays of the presentations can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceuticals...

August 27, 2025 1 EN
 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results ...

Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with licensee Novo Nordisk expected to submit IND Enrollment completion for SONATA Phase 3 study in both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) on target for 2026 Conference call and webcast at 8:30 am ET   THE WOODLANDS, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- (Na...

August 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch